KP 9

Drug Profile

KP 9

Latest Information Update: 10 Jul 2007

Price : $50

At a glance

  • Originator Burroughs Wellcome
  • Developer Krenitsky Pharmaceuticals
  • Class Antidepressants
  • Mechanism of Action Monoamine oxidase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 30 Nov 2000 No-Development-Reported for Depression in USA (Unknown route)
  • 20 Jun 1997 Preclinical development for Depression in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top